These observations suggest that CD44 and miR-199a play a very important role in regulating the cancer stem cell phenotype of CIC in ovarian cancer, supporting the hypothesis that CD44 may provide a novel therapeutic target for ovarian cancer. This evidence concerns the gene CD44 and ovarian cancer.